136 related articles for article (PubMed ID: 17428156)
21. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit.
Schneider DJ; Aggarwal A
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):903-13. PubMed ID: 15500435
[TBL] [Abstract][Full Text] [Related]
22. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.
Danzi GB; Capuano C; Sesana M; Mauri L; Sozzi FB
Am J Cardiol; 2006 Feb; 97(4):489-93. PubMed ID: 16461043
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].
Galli M; Vassanelli C
Ital Heart J Suppl; 2001 Oct; 2(10):1127-9. PubMed ID: 11723619
[No Abstract] [Full Text] [Related]
24. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
Kondo K; Umemura K
Clin Pharmacokinet; 2002; 41(3):187-95. PubMed ID: 11929319
[TBL] [Abstract][Full Text] [Related]
25. Tirofiban and emergency coronary surgery.
Shanmugam G
Eur J Cardiothorac Surg; 2005 Oct; 28(4):546-50. PubMed ID: 16126403
[TBL] [Abstract][Full Text] [Related]
26. Earlier administration of high-dose bolus tirofiban in STEMI increases benefit without increasing bleeding complications.
Cardiovasc J Afr; 2009; 20(4):268. PubMed ID: 19701545
[No Abstract] [Full Text] [Related]
27. Off-target effects of glycoprotein IIb/IIIa receptor inhibitors.
Ostrowska M; Adamski P; Koziński M; Navarese EP; Fabiszak T; Grześk G; Paciorek P; Kubica J
Cardiol J; 2014; 21(5):458-64. PubMed ID: 24526503
[TBL] [Abstract][Full Text] [Related]
28. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
[TBL] [Abstract][Full Text] [Related]
29. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
[TBL] [Abstract][Full Text] [Related]
30. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
31. Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives.
Valgimigli M; Campo G; Percoco G; Pellegrino L; Guardigli G; Ferrari R
Future Cardiol; 2006 Jan; 2(1):17-27. PubMed ID: 19804127
[TBL] [Abstract][Full Text] [Related]
32. Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.
Hantgan RR; Stahle MC; Jerome WG; Nagaswami C; Weisel JW
Thromb Haemost; 2002 May; 87(5):910-7. PubMed ID: 12038797
[TBL] [Abstract][Full Text] [Related]
33. Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease.
Warnholtz A; Ostad MA; Heitzer T; Goldmann BU; Nowak G; Munzel T
Am J Cardiol; 2005 Jan; 95(1):20-3. PubMed ID: 15619388
[TBL] [Abstract][Full Text] [Related]
34. Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis.
Schmitt-Sody M; Metz P; Gottschalk O; Zysk S; Birkenmaier C; Goebl M; von Schulze Pellengahr C; Veihelmann A; Jansson V
Inflamm Res; 2007 Oct; 56(10):414-20. PubMed ID: 18026698
[TBL] [Abstract][Full Text] [Related]
35. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
[TBL] [Abstract][Full Text] [Related]
36. Tirofiban for the treatment of ischaemic stroke.
Bukow SC; Daffertshofer M; Hennerici MG
Expert Opin Pharmacother; 2006 Jan; 7(1):73-9. PubMed ID: 16370924
[TBL] [Abstract][Full Text] [Related]
37. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
Witkowski A; Maciejewski P; Wasek W; Malek LA; Niewada M; Kaminski B; Drzewiecki J; Kosmider M; Kubica J; Ruzyllo W; Peruga JZ; Dudek D; Opolski G; Dobrzycki S; Gil RJ;
Eur Heart J; 2009 Jul; 30(14):1736-43. PubMed ID: 19376786
[TBL] [Abstract][Full Text] [Related]
38. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
[TBL] [Abstract][Full Text] [Related]
39. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
[TBL] [Abstract][Full Text] [Related]
40. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G
Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
